Modern healthcare depends on a basic assumption: when infections occur, clinicians will have medicines that can treat them. But antimicrobial resistance (AMR) is beginning to challenge that assumption at a systems level.
For many years, AMR has been discussed primarily as an infectious disease issue. That framing is accurate, but it is no longer sufficient. Resistant infections do not remain confined to infectious disease departments. They affect hospital operations, payer economics, surgical care, oncology, transplantation, intensive care, diagnostics, pharmacy planning, public health surveillance, and the broader resilience of healthcare delivery.
In other words, AMR is not only a microbiology problem. It is becoming a healthcare infrastructure problem.
The scale of the threat is already significant. A report from the World Health Organization estimates that bacterial AMR was associated with more than 4.7 million deaths globally in 2021 alone.1 In the United States, the CDC estimates that more than 2.8 million antimicrobial-resistant infections occur each year, and more than 35,000 people die as a result.2 These numbers are often cited to describe the public health burden of AMR, but they also point to a deeper operational challenge for health systems already under strain.
Resistant infections increase the complexity and cost of care
When antibiotics work as expected, infections can often be treated efficiently and predictably. When they do not, the consequences can ripple across the entire care pathway.
Patients may require longer hospital stays, more intensive monitoring, broader or more complex antimicrobial regimens, additional laboratory testing, isolation protocols, infectious disease consultations, and in some cases transfer to higher-acuity settings. Clinicians may need to use therapies that are less familiar, more toxic, more expensive, or more difficult to administer. Payers may face higher downstream costs tied to readmissions, complications, extended treatment, and avoidable utilization.
These are not abstract concerns. They directly affect hospital throughput, bed availability, pharmacy budgets, staffing demands, infection control resources, and care coordination. For health systems that are already managing capacity constraints, workforce shortages, and financial pressure, resistant infections add another layer of complexity.
And the economic consequences extend well beyond the hospital walls. WHO has noted that AMR can increase the need for more expensive and intensive care, prolong hospital stays, and affect productivity for patients and caregivers.3 The World Bank has estimated that AMR could result in $1 trillion in additional healthcare costs by 2050.4
AMR threatens core medical capabilities
The most important infrastructure affected by AMR may be the infrastructure we take for granted.
Modern medicine is built on the ability to prevent and treat infection. Surgery, cancer chemotherapy, organ transplantation, neonatal care, C-sections, joint replacements, dialysis access, trauma care, and the management of immunocompromised patients all depend on effective antimicrobials. When antibiotics lose reliability, these areas of care become riskier.
A patient receiving chemotherapy may be more vulnerable to infection because of a weakened immune system. A transplant recipient depends on immunosuppression to protect the transplanted organ, but that same immunosuppression increases susceptibility to infection. A patient undergoing orthopedic surgery or device implantation depends on infection prevention and treatment to support recovery. In each of these settings, effective antibiotics are not secondary tools. They are part of the foundation that makes the procedure or therapy possible.
This is why AMR should concern not only infectious disease specialists, microbiologists, and public health officials, but also hospital executives, surgeons, oncologists, transplant teams, intensivists, payers, policymakers, and anyone responsible for healthcare system performance.
The WHO has warned that AMR makes infections harder to treat and increases the risk associated with surgery, C-sections, cancer chemotherapy, and other medical procedures.5 That framing should change how healthcare leaders view the issue. AMR is not a distant threat to a narrow category of care; it is a direct threat to the reliability of modern healthcare.
Deployability matters as much as discovery
Scientific innovation is essential, but discovery alone is not enough.
A therapy that works in the laboratory but cannot be manufactured reliably, administered practically, accessed appropriately, or integrated into real-world workflows will have limited impact. For AMR innovation to matter at the system level, it must be designed with healthcare delivery in mind.
Deployability includes multiple considerations: route of administration, outpatient feasibility, storage and distribution, scalability, compatibility with diagnostic pathways, real-world prescribing workflows, and affordability. It also includes whether a new approach can help preserve hospital capacity by supporting treatment outside the inpatient setting when clinically appropriate.
This is one reason oral therapies remain so important in infectious disease. Oral treatment options can support outpatient care, step-down therapy, and more flexible management when clinically suitable. They are not the answer to every resistant infection, but they are an important part of a resilient antimicrobial ecosystem.
The same principle applies to approaches that may extend the utility of existing antibiotics. As bacteria evolve, the healthcare system cannot rely solely on a cycle of replacing one antibiotic with another and waiting for resistance to emerge again. Researchers are increasingly exploring mechanism-driven approaches that target the bacterial processes responsible for resistance, including mechanisms that allow bacteria to survive, replicate, or expel antibiotics before they can work.
AMR preparedness should be part of healthcare resilience planning
The healthcare industry has spent the past several years discussing resilience in the context of pandemics, supply chains, workforce capacity, cybersecurity, and emergency preparedness. AMR belongs in that conversation.
A resilient healthcare system must be able to prevent infections where possible, identify resistant pathogens quickly, use antimicrobials responsibly, protect vulnerable patients, maintain reliable supply chains, and support development of new therapeutic options. It must also have the policy and economic incentives needed to sustain antimicrobial innovation, because the traditional market model has not consistently supported the level of investment this public health challenge requires.
To overcome AMR, we need:
- Coordination across developers, hospitals, payers, regulators, public health agencies, policymakers, manufacturers, clinicians, and researchers
- Investment in rapid diagnostics and surveillance
- New incentives that recognize the societal value of antimicrobial innovation, even when responsible use means new therapies should be deployed carefully
Most importantly, overcoming AMR will require a broader understanding of what is at stake.
AMR is often described as a slow-moving pandemic. That phrase is useful, but it may not fully capture the way resistance is already affecting every aspect of healthcare today. AMR is a capacity issue, a cost issue, a preparedness issue, and a patient safety issue. It threatens the foundation that allows hospitals and health systems to deliver complex care safely. Treating AMR as a healthcare infrastructure priority is not only a matter of infectious disease preparedness; it is essential to preserving the reliability, capacity, and progress of modern medicine.
Author Bio
